Giant left atrial myxoma presenting as malignant heart failure and rapid atrial fibrillation in a young adult: a case report Authors: Carlos Solórzano Flores, Adolfo Izaguirre Membreño Published: 2026 ABSTRACT AbstractBackgroundPrimary cardiac tumours are rare, with cardiac myxomas representing the most common benign subtype in adults. Despite their benign histology, atrial myxomas may lead to significant clinical manifestations, including arrhythmias and heart failure. Giant left atrial myxomas are particularly uncommon, and their clinical presentation may vary depending on size, location, and associated haemodynamic effects.Case summaryA 37-year-old man presented with atrial fibrillation with rapid ventricular response, elevated NT-proBNP, cardiomegaly, and pleural effusion. Transthoracic and transoesophageal echocardiography demonstrated a massively dilated left atrium nearly occupied by a large intracavitary mass, accompanied by severe left ventricular systolic dysfunction (LVEF 15%–20%). Computed tomography identified a heterogeneous left atrial mass consistent with atrial myxoma. No Doppler evidence of significant mitral inflow obstruction was identified. The patient underwent surgical resection, and histopathology confirmed atrial myxoma. At 6-week follow-up, the patient demonstrated marked symptomatic improvement with recovery of left ventricular systolic function (LVEF 45%–50%).DiscussionThis case illustrates an uncommon presentation of a giant left atrial myxoma associated with atrial fibrillation and severe but reversible left ventricular dysfunction. The clinical course is consistent with tachycardia-induced cardiomyopathy rather than a purely obstructive mechanism. This case highlights the importance of recognizing arrhythmia-mediated ventricular dysfunction in patients with intracardiac masses, as well as the role of multimodality imaging and timely surgical intervention. Atrial myxomas may present with atrial fibrillation and secondary tachycardia-induced cardiomyopathy, even in the absence of significant mechanical obstruction. Atrial myxomas may present with atrial fibrillation and secondary tachycardia-induced cardiomyopathy, even in the absence of significant mechanical obstruction. Multimodality cardiac imaging is essential for accurate diagnosis, characterization, and surgical planning of intracardiac masses. Multimodality cardiac imaging is essential for accurate diagnosis, characterization, and surgical planning of intracardiac masses. Introduction Primary cardiac tumours are rare, with an estimated prevalence between 0.001% and 0.03%.1 Cardiac myxomas (CM) are the most frequent primary benign neoplasm, accounting for over 50% of all cases.2,3 Although histologically benign, these tumours are often considered clinically malignant due to their association with systemic embolization, intracardiac flow obstruction, and sudden cardiac death.3,4 Clinically, CMs typically involve a triad of constitutional, embolic, and obstructive symptoms.3 Left atrial myxomas frequently mimic mitral valve disease, leading to progressive pulmonary venous hypertension and dyspnoea.4 Most are detected at sizes between 3 and 5 cm, while giant myxomas, (>6 to 8 cm), are significantly rarer and may be associated with more pronounced haemodynamic effects.4,5 Cardiac tumours are recognized sources for arrhythmias, through atrial stretching or mechanical irritation. The development of rapid atrial fibrillation in the setting of a massive atrial mass can precipitously worsen cardiac output.6 We report a case of a 37-year-old male presenting with a giant left atrial myxoma and severe systolic dysfunction in the setting of atrial fibrillation. This case highlights the importance of early recognition, multimodality imaging, and timely surgical intervention, as well as the potential role of tachycardia-induced cardiomyopathy in patients with intracardiac masses. Summary figure Case presentation A 37-year-old man with a recent diagnosis of Helicobacter pylori infection and a medical history for attention-deficit/hyperactivity disorder treated with amphetamine–dextroamphetamine and herpes simplex virus type 1 on valacyclovir presented to the emergency department with concern for possible medication-related adverse effects (day 0). He reported several days of progressive lightheadedness, nausea, vomiting, diarrhoea, palpitations and recent abdominal weight gain. He denied chest pain, dyspnoea, fever, night sweats, or unintentional weight loss. There was no relevant family history of cardiovascular disease. On presentation, heart rate was 155 b.p.m. and blood pressure 110/65 mmHg. Physical examination revealed an irregularly irregular rhythm, mild bibasilar crackles, abdominal distension, and peripheral oedema, without murmurs or gallops. Electrocardiography showed atrial fibrillation with rapid ventricular response. Laboratory studies were notable for an NT-proBNP of 8620 pg/ml and serum creatinine of 1.22 mg/dl. Initial management included intravenous metoprolol 5 mg followed by oral metoprolol tartrate 25 mg twice daily, oral amiodarone 400 mg every 12 h, intravenous unfractionated heparin, and spironolactone 25 mg daily. Chest radiography demonstrated cardiomegaly with a small-to-moderate left pleural effusion. Computed tomography (CT) angiography of the chest revealed a large left atrial soft-tissue mass measuring 9.3 × 9.2 × 7.0 cm. The mass demonstrated heterogeneous attenuation without evidence of local invasion, most consistent with atrial myxoma. CT of the abdomen and pelvis showed ascites, gallbladder wall oedema, and diffuse body wall oedema, consistent with systemic congestion (Figure 1). (A) Twelve-lead electrocardiogram obtained on presentation demonstrating atrial fibrillation with rapid ventricular response, characterized by an irregularly irregular rhythm, absence of discernible P waves. (B) Admission chest radiograph showing cardiomegaly and left pleural effusion, consistent with systemic congestion. (C) Axial contrast-enhanced CT images of the chest demonstrating a large left atrial mass with heterogeneous attenuation and without evidence of local invasion, occupying the majority of the left atrial cavity. On day 1, transthoracic echocardiography (TTE) revealed a dilated left ventricle with severely reduced systolic function (LVEF 15%–20%), and a massively dilated left atrium nearly occupied by a large intracavitary mass. Mild mitral and tricuspid regurgitation were also observed. No significant transmitral gradient or Doppler evidence of functional mitral obstruction was identified. Transoesophageal echocardiography confirmed the presence of a large, fixed left atrial mass, moderate mitral regurgitation, right ventricular dilation, and an estimated LVEF of 25%–30%. (Figure 2) Despite tachyarrhythmia and reduced left ventricular systolic function, the patient remained haemodynamically stable, without hypotension, shock, or evidence of tissue hypoperfusion. (A) Apical four chamber transthoracic echocardiographic view confirming the presence of the left atrial mass. (B) Transoesophageal echocardiographic view demonstrating a large heterogeneous mass occupying the left atrium. Coronary angiography on day 2 revealed mild non-obstructive coronary artery disease and haemodynamics consistent with group 2 pulmonary hypertension. The potential role of stimulant therapy as a precipitant for the tachyarrhythmia was considered, though no evidence of myocarditis was found. Given the size of the mass and the severity of the clinical presentation, urgent surgical resection was performed on day 4. Intraoperatively, a left atrial mass measuring approximately 10 × 9 cm was excised. Gross pathology revealed a 246-g yellow-tan, multilobulated myxoid mass measuring 9.5 × 8.2 × 5.5 cm with a smooth, glistening surface (Figure 3). Histopathology confirmed atrial myxoma. Post-operatively, the patient recovered uneventfully and was discharged (day 10) with marked symptomatic improvement (NYHA class II). Gross pathology of the left atrial mass. Resected left atrial tumour showing a large, multilobulated, yellow-tan, myxoid mass with a smooth, and glistening surface. At 6-week outpatient follow-up, the patient reported marked symptomatic improvement, with resolution of congestion and functional status improving to NYHA class I. Repeat TTE demonstrated significant recovery of left ventricular systolic function, with LVEF improving from 15% to 20% at presentation to approximately 45%–50%. Left ventricular dimensions were reduced compared to baseline, while the left atrium remained dilated. The patient was in sinus rhythm at follow-up. Discussion This case illustrates an uncommon presentation of a giant left atrial myxoma causing acute decompensated heart failure with severe left ventricular systolic dysfunction. The clinical expression of CM is heterogeneous, largely determined by size, mobility, and intracardiac location.1 The defining features of this case, a tumour volume exceeding 9 × 9 cm and a preoperative LVEF of 15%–30%, represents an uncommon presentation in the existing literature. Most atrial myxomas present with symptoms of pseudostenosis, mimicking mitral valve disease with preserved ventricular contractility.4 In contrast, our patient presented with severe systolic failure and systemic congestion (ascites and oedema). This degree of dysfunction is likely multifactorial.6 First, the large size of the mass (246 g, 9.3 × 9.2 cm) may have influenced left atrial haemodynamics; however, no Doppler evidence of significant transmitral obstruction was identified, suggesting that its direct impact on left ventricular filling was likely limited. Giant myxomas described in recent literature typically range from 6 to 8 cm.6,7 The tumour in our patient significantly exceeded these dimensions, which may have contributed to atrial remodelling and the markedly elevated NT-proBNP level (8620 pg/ml) observed in this case, a value more than 10 times higher than those reported in similar giant tumour cases.7 Second, the concurrent rapid atrial fibrillation (155 b.p.m.) likely contributed a component of tachycardia-induced cardiomyopathy. Cardiac tumours can mechanically irritate the atrial myocardium or invade conductive tissue, serving as a substrate for refractory arrhythmias.5 In this context, it is possible that the patient’s stimulant therapy likely acted as a pharmacological trigger, lowering the arrhythmogenic threshold in a structurally remodelled atrium.8 In this patient, loss of atrial contribution to ventricular filling together with sustained tachycardia likely contributed to impaired cardiac function. The elevated NT-proBNP level and systemic congestion are therefore consistent with heart failure in the setting of arrhythmia-mediated ventricular dysfunction, rather than a purely obstructive mechanism. Differentiating a giant myxoma from a large intracavitary thrombus is a critical diagnostic challenge, particularly in the presence of atrial fibrillation.3,9 Atrial thrombi can mimic myxomas, especially when not clearly attached to the left atrial appendage, creating a diagnostic conundrum that alters management.9 In our case, multimodality imaging was decisive. While TTE identified the mass, CT provided essential characterization of the tissue density and confirmed the absence of direct invasion into surrounding structures, a hallmark of malignancy.3,6 The yellow-tan, gelatinous gross pathology confirmed the diagnosis of a myxoma, consistent with the villous or ‘myxoid’ subtype, which is historically associated with a higher risk of embolization and constitutional symptoms.1 Immediate surgical resection remains the gold standard for management, carrying a generally favourable prognosis even in high-risk presentations.10 Early mortality rates for myxoma resection are low, approximately 1.3% to 2.6%, and that long-term survival is excellent, provided the resection is complete.10,11 In our case, the patient demonstrated marked clinical and echocardiographic improvement at follow-up, with recovery of left ventricular systolic function. This evolution is consistent with tachycardia-induced cardiomyopathy as the primary mechanism of ventricular dysfunction. Long-term surveillance is mandatory, as recurrence rates, while low (0.5 per 1000) are documented, particularly in younger patients or those with familial syndromes such as Carney complex.2,4 Furthermore, recent longitudinal data suggest that survivors of cardiac tumours may have a slightly elevated risk of developing extracardiac neoplasms, warranting holistic long-term follow-up.11 This case is important for several reasons. It demonstrates that giant atrial myxomas may present with severe, potentially reversible cardiomyopathy, a manifestation that is not widely emphasized in large series. In addition, it highlights the role of atrial fibrillation and atrial remodelling as important contributors to ventricular dysfunction in patients with intracardiac masses. Finally, it underscores the importance of maintaining diagnostic suspicion for intracardiac masses in patients with unexplained heart failure, atrial arrhythmias, or systemic congestion, even when symptoms are initially attributed to extracardiac causes. By integrating clinical findings with imaging and pathologic confirmation, this case complements existing reviews and cohort studies while contributing to the understanding of myocardial dysfunction in patients with cardiac tumours. It reinforces the need for early cardiac imaging in atypical presentations and supports timely surgical intervention to prevent progressive cardiac dysfunction.